Altered fibrinolysis and platelet function in the development of vascular complications of diabetes

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 4, 1996, Pages 355-360

  Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343450341     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199608000-00011     Document Type: Article

References (75)

1. Clark M, Vinicor F: Introduction: risks and benefits of intensive management in NIDDM: the Fifth Regenstrief Conference. Ann Intern Med 1996, 124:81-84. The introduction to this symposium and the symposium itself provide a thorough and balanced view of controversies surrounding the potential role of insulin or its precursors in the pathogenesis of macroangiopathy and the utility of stringent glycemic control in its prevention.
2. Curb J, Rodriguez B, Burchfiel C, Abbott R, Chiu D, Yano K: Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995, 91:2591-2595.
3. Bao W, Srinivasan R, Berenson G: Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults: the Bogalusa Heart Study. Circulation 1996, 93:54-59.
4. Klein R, Klein B, Moss S: Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996, 124:90-96.
5. Dorin R, Shah V, Kaplan D, Vela B, Zager P: Regulation of aldose reductase gene expression in renal cortex and medulla of rats. Diabetologia 1995, 38:46-54.
6. Soulisliparota T, Cooper M, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995, 38:387-394.
7. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
8. Henry R: Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:97-103.
9. Laakso M: Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:127-130.
10. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:136-145.
11. Genuth S: Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:104-109.
12. Lee E, Howard B, Savage P, Cowan L, Fabsitz R, Oopik A, Yeh J, Go O, Robbins D, Welty T: Diabetes and impaired glucose tolerance in three American Indian populations aged 54-74 years: the Strong Heart Study. Diabetes Care 1995, 18:611-617. An important set of observations indicating the lack of consistency between the severity of deranged intermediary metabolism associated with diabetes and the evolution of macroangiopathy.
13. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B: Amelioration of the inhibition of fibrinolysis in obese elderly subjects by moderate caloric restriction. Am J Clin Nutr 1996, in press. Observations indicating that even modest caloric restriction may exert favorable effects on the fibrinolytic system in patients with obesity, implying that reduction of insulin resistance may be a contributing factor.
14. Nagi D, Yudkin J: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993, 16:653-655.
15. Nolan J, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994, 331:1188-1193. A promising report regarding a novel class of pharmacologic agents, the triazolidinediones, that appear to improve glucose tolerance by diminishing insulin resistance through several mechanisms. These mechanisms include diminution of hepatic gluconeogenesis and enhancement of peripheral utilization of glucose by adipose tissue and skeletal muscle, perhaps through modulation of glucose transport and glucose transporter gene expression.
16. Stern M: Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 1995, 44:369-374.
17. Wingard D, Barrettconnor E, Ferrara A: Is insulin really a heart disease risk factor? Diabetes Care 1995, 18:1299-1304.
18. Mohamedali V, Gould M, Gillies S, Goubet S, Yudkin J, Haines A: Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects: evidence against a modulating role for insulin. Diabetologia 1995, 38:1110-1116.
19. Wareham N, Byrne C, Hales C: Role of insulin and proinsulin in diabetic vascular disease. Metabolism 1995, 44:76-82.
20. Ridray S: Hyperinsulinemia and smooth muscle cell proliferation. Int J Obes Relat Metab Disord 1995, 19:S39-S51.
21. Vague P, Raccah D, Scelles V: Hypofibrinolysis and the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995, 19:S11-S15. A comprehensive review by workers who have contributed extensively to the elucidation of associations between insulin resistance and impaired fibrinolysis.
22. Leurs P, van Oerle R, Hamulyak K, Wolffenbuttel B: Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995, 44:80-84.
23. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakada T, Miyata T: Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995, 14:1114-1120.
24. Foyle W-J, Carstensen E, Fernandez M, Yudkin J: A longitudinal study of associations of microalbuminuria with the insulin resistance syndrome and sodium-lithium countertransport in non-diabetic subjects. Arterioscler Thromb Vasc Biol 1995, 15:1330-1337.
25. Pinkney J, Denver A, Mohamed-Ali V, Foster C, Yudkin J: Insulin resistance in non-insulin dependent diabetes mellitus is associated with microalbuminuria independently of ambulatory blood pressure. J Diabetes Complications 1996, in press.
26. Vaughan D, Lazos S, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995-1001. A report implicating relationships between the renin-angiotensin system and the fibrinolytic systems. These relationships may be mediated by effects of metabolites of angiotensin on elaboration of PAI-1 from endothelial cells.
27. Kerins D, Hao Q, Vaughan D: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995, 96:2515-2520. This paper complements the report from Vaughan et al. (J Clin Invest 1995, 95:995-1001), providing additional mechanistic information.
28. van Leeuwen R, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G: Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994, 90:362-368.
29. Ridker P, Gaboury C, Conlin P, Seely E, Williams G, Vaughan D: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993, 87:1969-1973.
30. Olson JA, Shiverick KT, Ogilvie S, Buhi W, Raizada M: Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci U S A 1991, 88:1928-1932.
31. Schneider D, Sobel B: Effect of diabetes on the coagulation and fibrinolytic systems and their implications for atherogenesis. Coron Artery Dis 1992, 3:26-32.
32. Juhan-Vague I, Alessi M, Declerck P: Pathophysiology of fibrinolysis. Baillieres Clin Haematol 1995, 8:329-343.
33. Tracy R, O'Agostino R: The relationship of fibrinogen and diabetes status in whites, blacks and Hispanics: results from the Insulin Resistance and Diabetes Study (IRAS) [abstract]. Diabetes 1995, 44:123a.
34. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo J: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995, 332:635-641.
35. Ditschuneit H, Fletcher-Mors M, Adler G: Fibrinogen in obesity before and after weight reduction. Obes Res 1995, 3:43-48.
36. Mansfield M, Heywood D, Grant P: Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996, 16:160-164.
37. Gruden G, Cavallo-Perin G, Romagnoli R, Olivetti C, Frezet D, Pagano G: Prothrombin fragment 1.2 and antithrombin III-thrombin complex in microalbuminuric type 2 diabetic patients. Diabet Med 1995, 11:485-488.
38. Torr-Brown S, Sobel B: Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thromb Res 1994, 75:473-477. Data indicating a paradoxical relationship between PAI-1 in plasma and platelets harvested from patients with diabetes. Suggests that augmented PAI-1 in blood may come, in part, from degranulation of platelets in patients with diabetes, in keeping with the observed hyperactivity of these cell elements.
39. Zentay Z, Raguwanshi M, Reddi A, Lasker N, Dasmahapatra A, Aviv A: Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM. J Diabetes Complications 1995, 9:74-80.
40. Caimi G, Lo-Presti R, Montana M, Canino B, Ventimiglia G, Romano A, Catania A, Sarno A: Membrane fluidity, membrane lipid pattern, and cytosolic Ca2+ content in platelets from a group of type II diabetic patients with macrovasuclar complications. Diabetes Care 1995, 18:60-63.
41. Tschoepe D, Driesch E, Schwippert B, Nieuwenhuis H, Gries F: Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes 1995, 44:890-894.
42. Kahn N, Bauman W, Sinha A: Insulin-induced release of plasminogen activator from human blood platelets. Am J Physiol 1995, 268:H117-H124. Data implicating insulin as a mediator of degranulation of platelets and elaboration of protein constituents within granules.
43. Joki R, Klein R, Lopesvirella M, Colwell J: Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care 1995, 18:1150-1155. Information consistent with the implications of the studies by Torr-Brown and Sobel (Thromb Res 1994, 75:473-477) and Kahn et al. (Am J Physiol 1995, 268:H117-H124), among others.
44. Ginon I, Talussot C, Ponsin G, Ciavatti M: Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes. Acta Diabetol 1995, 32:170-175.
45. Kim S, Ryu G, Lee I, Koh J, Min B, Lee H: Adhered platelet morphology in diabetes mellitus. Diabetes Metab 1995, 21:50-53.
46. Nordt T, Sawa H, Fujii S, Sobel B: Induction of plasminogen activiator inhibitor type 1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764-770. Direct induction of PAI-1 by insulin and its precursors in vivo is demonstrated in this report. Proinsulin and insulin were administered to rabbits and PAI-1 gene expression was characterized within vessel walls as well as with respect to PAI-1 content of blood.
47. Salomaa V, Stinson V, Kark J, Folsom A, Davis C: Association of fibrinolytic parameters with early atherosclerosis. Circulation 1995, 91:284-290.
48. Tracy R, Bovill E: Hemostasis and risk of ischemic disease: epidemiologic evidence with emphasis on the elderly. In Acute Coronary Care in the Thrombolytic Era. Edited by Califf R, Mark D, Wagner G. St. Louis: Mosby Year Book; 1995:27-43.
49. Nordt T, Schneider D, Sobel B: Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation 1994, 89:321-330.
50. Schneider D, Ricci M, Sobel B: Biphasic mural proteolysis in atherogenesis [abstract]. J Am Coll Cardiol 1995, 27:242.
51. Galis Z, Sukhova G, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995, 9:974-980.
52. McGill J, Schneider D, Arfken C, Lucore C, Sobel B: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994, 43:104-109. Delineation of impaired fibrinolysis under basal conditions and with physiologic stress in subjects with NIDDM and demonstration of concordance between the impairment and the magnitude of insulinemia indicative of insulin resistance.
53. Tracy R, Kuller L, Psaty B, Cushman M, Meilahn E, Smith N: C-reactive protein and incidence of cardiovascular disease in older women: the Rural Health Promotion Project and the Cardiovascular Health Study [abstract]. Circulation 1996, 93:622.
54. Padro T, Emeis J, Steins M, Schmid K, Kienast J: Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995, 15:893-902.
55. He C, Wilhelm S, Pentland A, Marmer B, Grant G, Eisen A, Goldberg G: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 1989, 86:2632-2636.
56. Schneider D, Baumann P, Absher M, Sobel B: Augmented porcine coronary arterial expression of plasminogen activator inhibitor-type (PAI-1) in human atherosclerotic arteries and its potentiation by insulin [abstract]. Circulation 1995, 92:170.
57. Sobel B: Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert. Circulation 1996, 93:1613. A review of the implications of a recent clinical alert from the National Institutes of Health regarding potential pathogenetic effects of insulin on the predisposition to macroangiopathy in patients with diabetes subjected to angioplasty or coronary surgery.
58. Fattal P, Schneider D, Sobel B, Billadello J: Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992, 267:12412-12415.
59. Nordt T, Klassen K, Schneider D, Sobel B: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arteriosclerosis Thromb 1993, 13:1822-1928.
60. Noda-Heiny H, Fujii S, Sobel B: Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. Circ Res 1993, 72:36-43.
61. Lundgren C, Sawa H, Brown S, Nordt T, Sobel B, Fujii S: Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996, 93:106-110.
62. Scelles V, Alessi M, Raccah D, Juhan-Vague I, Vague P: Plasma plasminogen activator inhibitor activity in rats with nutritionally induced insulin resistance. Thromb Haemost 1995, 74:806-807.
63. Gray R, Vidya M, Patterson D, Yudkin J: Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost 1995, 73:261-267.
64. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale P, Lovik A, Birkeland K: Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995, 44:611-616.
65. Nordt T, Kornas K, Fujii S, Sobel B: Gemfibrozil inhibits the induction of plasminogen activator inhibitor type-1 by insulin and its precursors [abstract]. Circulation 1995, 91:555.
66. Brown S, Sobel B, Fujii S: Attenuation of the synthesis of plasminogen activator inhibitor type-1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation 1995, 92:767-772.
67. Jain S, Nagi D, Slavin B, Lumb P, Yudkin J: Insulin therapy in non-insulin-dependent diabetic subjects suppresses concentrations of proinsulin-llke molecules and plasminogen activator inhibitor independently from glycaemic control. Diabetes Med 1993, 10:27-32.
68. Mansfield M, Strickland M, Grant P: Plasminogen activator inhibitor-1 concentrations and cardiovascular risk markers in first-degree relatives of patients with NIDDM. Circulation 1996, in press.
69. Panahloo A, Mohamed-Ali V, Lane A, Humphries S, Yudkin J: Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995, 44:37-42. An additional contribution from major contributors in the field demonstrating that a recently recognized polymorphism is a major determinant of augmentation of PAI-1 activity in patients with NIDDM.
70. National Heart, Lung, and Blood Institute, National Institutes of Health: Clinical alert: bypass over angioplasty for patients with diabetes. September 21, 1995.
71. Barbash G, White H, Modan M, Van de Werf F, for the Investigators of the International Tissue Plasminogen Activators/Streptokinase Mortality Trial: Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993, 22:707-713.
72. UGDP: A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes: VI: supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976, 25:1129-1153.
73. Alessi M, Anfosso F, Henry M, Peiretti F, Nalbone G, Juhan-Vague I: Up-regulation of PAI-1 synthesis by insulin and proinsulin in Hep G2 cells but not in endothelial cells. Fibrinclysis 1995, 9:237-242.
74. Zimlichman R, Zeidel L, Gefel D, Barg J, Shahar C, Nakash Y, Matas Z, Gass S, Eliahou H: Insulin induces medial hypertrophy of myocardial arterioles in rats. Am J Hypertens 1995, 8:915-920. Additional information implicating insulin as a directly pathogenetic moiety that may modify proliferation of vascular smooth muscle cells in arterial walls.
75. Hancu N, Netea M, Iancu S: Serum lipoprotein(a) is increased in hypertensive NIDDM patients. Diabetes Care 1995, 18:879-880.